PerkinElmer to acquire antibody and reagents provider BioLegend

Life science research solutions company PerkinElmer, Inc. (MA, USA) announced its plans to acquire life science antibody and reagents provider BioLegend (CA, USA) for USD$5.25 billion. The transaction is expected to be the largest in PerkinElmer’s history, with the goal to close the deal by the end of the 2021 calendar year. BioLegend, a privately held company with more than 700 employees, will expand the existing life science franchise within PerkinElmer, with new segments and the addition of BioLegend’s campus in San Diego to PerkinElmer’s roster of global offices. Prahlad Singh, President and Chief Executive Officer of PerkinElmer, commented: “We...